Moderna's ba.4/ba.5 targeting bivalent booster, mrna-1273.222, meets primary endpoint of superiority against omicron variants compared to booster dose of mrna-1273 in phase 2/3 clinical trial

In a phase 2/3 trial in over 500 adults, mrna-1273.222, induced significantly higher neutralizing antibody titers against ba.4/ba.5 compared to a booster dose of mrna-1273 results build upon data recently published in the new england journal of medicine that confirmed superiority of the company's ba.1 bivalent vaccine, mrna-1273.214, neutralizing titers against multiple omicron variants compared to a booster dose of mrna-1273 both of the company's updated bivalent boosters (mrna-1273.214 and mrna-1273.222) showed neutralizing titers against bq.1.1, an emerging threat globally, in an exploratory analysis safety and tolerability of mrna-1273.214 and mrna-1273.222 were similar to a booster dose of mrna-1273 and adverse events were generally lower than the second dose of the primary series cambridge, ma / accesswire / november 14, 2022 / moderna, inc., (nasdaq:mrna) a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that both of moderna's bivalent omicron-targeting booster candidates (mrna-1273.214 and mrna-1273.222) trigger a superior antibody response compared to a booster dose of mrna-1273, the company's prototype vaccine, against omicron (ba.4/ba.5) in phase 2/3 clinical trials. both bivalent vaccines also met non-inferiority immunogenicity criteria to the original strain.
MRNA Ratings Summary
MRNA Quant Ranking